Literature DB >> 24630791

Periprocedural glycemic control in patients with diabetes mellitus undergoing coronary angiography with possible percutaneous coronary intervention.

Binita Shah1, Jeffrey S Berger2, Nicholas S Amoroso3, Xingchen Mai3, Jeffrey D Lorin3, Ann Danoff4, Arthur Z Schwartzbard3, Iryna Lobach5, Yu Guo5, Frederick Feit3, James Slater3, Michael J Attubato3, Steven P Sedlis3.   

Abstract

Periprocedural hyperglycemia is an independent predictor of mortality in patients who underwent percutaneous coronary intervention (PCI). However, periprocedural management of blood glucose is not standardized. The effects of routinely continuing long-acting glucose-lowering medications before coronary angiography with possible PCI on periprocedural glycemic control have not been investigated. Patients with diabetes mellitus (DM; n = 172) were randomized to continue (Continue group; n = 86) or hold (Hold group; n = 86) their clinically prescribed long-acting glucose-lowering medications before the procedure. The primary end point was glucose level on procedural access. In a subset of patients (no DM group: n = 25; Continue group: n = 25; and Hold group: n = 25), selected measures of platelet activity that change acutely were assessed. Patients with DM randomized to the Continue group had lower blood glucose levels on procedural access compared with those randomized to the Hold group (117 [97 to 151] vs 134 [117 to 172] mg/dl, p = 0.002). There were two hypoglycemic events in the Continue group and none in the Hold group, and no adverse events in either group. Selected markers of platelet activity differed across the no DM, Continue, and Hold groups (leukocyte platelet aggregates: 8.1% [7.2 to 10.4], 8.7% [6.9 to 11.4], 10.9% [8.6 to 14.7], p = 0.007; monocyte platelet aggregates: 14.0% [10.3 to 16.3], 20.8% [16.2 to 27.0], 22.5% [15.2 to 35.4], p <0.001; soluble p-selectin: 51.9 ng/ml [39.7 to 74.0], 59.1 ng/ml [46.8 to 73.2], 72.2 ng/ml [58.4 to 77.4], p = 0.014). In conclusion, routinely continuing clinically prescribed long-acting glucose-lowering medications before coronary angiography with possible PCI help achieve periprocedural euglycemia, appear safe, and should be considered as a strategy for achieving periprocedural glycemic control.
Copyright © 2014 Elsevier Inc. All rights reserved.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24630791      PMCID: PMC4018663          DOI: 10.1016/j.amjcard.2014.01.428

Source DB:  PubMed          Journal:  Am J Cardiol        ISSN: 0002-9149            Impact factor:   2.778


  30 in total

1.  Platelet reactivity characterized prospectively: a determinant of outcome 90 days after percutaneous coronary intervention.

Authors:  S S Kabbani; M W Watkins; T Ashikaga; E F Terrien; P A Holoch; B E Sobel; D J Schneider
Journal:  Circulation       Date:  2001-07-10       Impact factor: 29.690

2.  Increased platelet reactivity and circulating monocyte-platelet aggregates in patients with stable coronary artery disease.

Authors:  M I Furman; S E Benoit; M R Barnard; C R Valeri; M L Borbone; R C Becker; H B Hechtman; A D Michelson
Journal:  J Am Coll Cardiol       Date:  1998-02       Impact factor: 24.094

3.  Leukocyte activation with platelet adhesion after coronary angioplasty: a mechanism for recurrent disease?

Authors:  J K Mickelson; N M Lakkis; G Villarreal-Levy; B J Hughes; C W Smith
Journal:  J Am Coll Cardiol       Date:  1996-08       Impact factor: 24.094

Review 4.  Evolving therapeutic options for type 2 diabetes mellitus: an overview.

Authors:  Robert M Guthrie
Journal:  Postgrad Med       Date:  2012-11       Impact factor: 3.840

5.  Thromboxane biosynthesis and platelet function in type II diabetes mellitus.

Authors:  G Davì; I Catalano; M Averna; A Notarbartolo; A Strano; G Ciabattoni; C Patrono
Journal:  N Engl J Med       Date:  1990-06-21       Impact factor: 91.245

6.  The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.

Authors:  D M Nathan; S Genuth; J Lachin; P Cleary; O Crofford; M Davis; L Rand; C Siebert
Journal:  N Engl J Med       Date:  1993-09-30       Impact factor: 91.245

7.  Usefulness of hyperglycemia in predicting renal and myocardial injury in patients with diabetes mellitus undergoing percutaneous coronary intervention.

Authors:  Bryan J Robertson; Joseph A Gascho; Robert A Gabbay; Patrick H McNulty
Journal:  Am J Cardiol       Date:  2004-10-15       Impact factor: 2.778

8.  Optimal glycemic control is associated with a lower rate of target vessel revascularization in treated type II diabetic patients undergoing elective percutaneous coronary intervention.

Authors:  Roberto A Corpus; Peter B George; John A House; Simon R Dixon; Steven C Ajluni; William H Devlin; Gerald C Timmis; Mamtha Balasubramaniam; William W O'Neill
Journal:  J Am Coll Cardiol       Date:  2004-01-07       Impact factor: 24.094

9.  Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

Authors: 
Journal:  Lancet       Date:  1998-09-12       Impact factor: 79.321

10.  Impaired endothelium-dependent and independent vasodilation in patients with type 2 (non-insulin-dependent) diabetes mellitus.

Authors:  G E McVeigh; G M Brennan; G D Johnston; B J McDermott; L T McGrath; W R Henry; J W Andrews; J R Hayes
Journal:  Diabetologia       Date:  1992-08       Impact factor: 10.122

View more
  2 in total

1.  A risk score for prediction of hyperglycemia at coronary angiography.

Authors:  Binita Shah; Joseph Burdowski; Iryna Lobach; Eugenia Gianos; Steven P Sedlis
Journal:  JACC Cardiovasc Interv       Date:  2014-09-17       Impact factor: 11.195

2.  Glycemic Control in Coronary Revascularization.

Authors:  Francisco Ujueta; Ephraim N Weiss; Steven P Sedlis; Binita Shah
Journal:  Curr Treat Options Cardiovasc Med       Date:  2016-02
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.